Call for Abstract
Scientific Program
4th International Conference and Exhibition on Biologics and Biosimilars, will be organized around the theme “The future of next generation Biologics and Biosimilars”
Biosimilars 2015 is comprised of 14 tracks and 94 sessions designed to offer comprehensive sessions that address current issues in Biosimilars 2015.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1Licensing of biosimilars
- Track 1-2Biosimilars regulation
- Track 1-3Patent issues
- Track 1-4BLA filing for biosimilars
- Track 1-5Regulatory prospects of BRIC countries
- Track 1-6A paradigm of traditional generics to biosimilars
- Track 1-7Biowaiver approval for Biosimilars
- Track 1-8Generic Biosimilars
- Track 2-1Recombinant blood products
- Track 2-2Recombinant vaccines
- Track 2-3Growth hormones
- Track 2-4Insulin Biosimilars
- Track 2-5Biosimilar peptides
- Track 2-6Recombinant therapeutic proteins
- Track 2-7Biosimilars in cancer treatment
- Track 2-8Biosimilar monoclonal antibodies
- Track 2-9Biosimilars interferon
- Track 2-10Biosimilars in rheumatic diseases
- Track 3-1Biosimilars Clinical Trials
- Track 3-2Biosimilars Clinical Studies
- Track 3-3Clinical trials on major diseases
- Track 3-4Risk management, and quality affairs
- Track 3-5Case studies, and clinical models
- Track 3-6Transgenic animals
- Track 3-7 Targeted cell line development
- Track 3-8Clinical PK/PD studies
- Track 3-9Toxicological studies
- Track 3-10Aspects of genotoxicity tests
- Track 4-1Biologics in diabetes
- Track 4-2EBiologics in autoimmune disease
- Track 4-3Biologics in cardivascular diseases
- Track 4-4Biologics in digestive disorders
- Track 4-5Biologics in genetic disorders
- Track 4-6Biologics in neurologic disorders
- Track 4-7Biologics in respiratory disorders
- Track 4-8Biologics for Psoriasis
- Track 4-9Biologics In Cancer
- Track 5-1Global impact of biosimilars over generics
- Track 5-2Economic aspect towards biosimilars
- Track 5-3Biosimilars in global market
- Track 5-4Investment and returns on biosimilars
- Track 5-5Cost and risk management
- Track 5-6Adopting innovative mechanisms such as risk-sharing arrangement
- Track 5-7European market for biosimilars
- Track 5-8Global P&R models for the biosimilars and generics market
- Track 6-1Biotechnology medicinal products for different drugs
- Track 6-2Challenges faced in developing biosimilars
- Track 6-3Future of next generation biosimilars
- Track 6-4Biopharmaceuticals development
- Track 7-1Biosimilar Bioanalytical methods
- Track 7-2Biosimilar Formulation
- Track 7-3Bioassay for comparability and potency testing
- Track 7-4Biosimilar GMP protein analysis
- Track 7-5Biosimilar LC/MS analysis for discovery, preclinical, and clinical programs
- Track 7-6Biosimilar Electrophoresis
- Track 7-7Biosimilar Multimodal techniques
- Track 8-1Strategies for the bioequivalence assessment of topical dosage forms
- Track 8-2Bioequivalence assessment of respiratory dosage forms
- Track 8-3Bioequivalence approaches for transdermal dosage forms
- Track 8-4Evaluation of highly variable drugs and drug products
- Track 9-1BCS biowaivers
- Track 9-2Preclinical and clinical testing for oral drug delivery
- Track 9-3Waiver for In vivo bioavailability or bioequivalence
- Track 9-4Consideration of biowaiver extensions for BCS class III drugs
- Track 9-5In vitro diffusion cells for dissolution testing in formulation development
- Track 9-6Dissolution testing in drug formulation
- Track 9-7In vitro preclinical ADME/BCS testing
- Track 9-8In vitro drug product research
- Track 10-1Transgenic plants
- Track 10-2Post translational genetics
- Track 10-3Fermentation culture
- Track 10-4Molecular farming
- Track 11-1Current problems in pharmacovigilance
- Track 11-2Role of pharma industries in the improvement of pharmacovigilance system
- Track 11-3Detection and evaluation of drug safety signals
- Track 11-4Adverse drug reactions with pharmaceutical products
- Track 11-5Good pharmacovigilance practice and pharmacoepidemiology
- Track 12-1Pharma Patent Scenario
- Track 12-2Criteria for Patentability and Patent Claims
- Track 12-3Critical research issues
- Track 12-4Patentable subject matter
- Track 12-5Recent Patent disputes and litigations
- Track 13-1Current concepts of drugs and biologics
- Track 13-2Unique considerations for biologics
- Track 13-3Early clinical development essentials
- Track 13-4Late clinical development essentials
- Track 13-5Drug Safety essentials
- Track 13-6Advertising, promotion and labeling essentials
- Track 13-7Cancer therapeutics
- Track 13-8Comparability for Biologics
- Track 14-1Biosimilars China
- Track 14-2Biosimilars India
- Track 14-3Biosimilars USA
- Track 14-4Biosimilars Europe